Royalty Pharma financials
$58.22−0.26%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $674.1M | $630.6M | $622.0M | $609.3M | $578.7M | $568.2M | $593.6M | $564.7M | $537.3M | $568.0M | $596.1M | $536.3M |
| Gross profit | $674.1M | $630.6M | $622.0M | $609.3M | $578.7M | $568.2M | $593.6M | $564.7M | $537.3M | $568.0M | $596.1M | $536.3M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | $133.1M | $563.0M | $388.4M | $427.2M | $209.8M | $534.2M | $361.5M | $735.1M | $269.6M | -$73.8M | $612.9M | $151.4M |
| Net income | $17.9M | $294.7M | $214.2M | $288.2M | $32.2M | $239.3M | $208.2M | $544.0M | $102.0M | $4.8M | $494.3M | $72.1M |
| Net margin | 2.7% | 46.7% | 34.4% | 47.3% | 5.6% | 42.1% | 35.1% | 96.3% | 19.0% | 0.8% | 82.9% | 13.4% |
| Diluted EPS | $0.04 | $0.67 | $0.38 | $0.67 | $0.07 | $0.55 | $0.35 | $1.21 | $0.23 | $0.01 | $0.83 | $0.16 |
| EBITDA | $133.1M | $435.0M | $707.3M | $439.3M | $209.8M | $407.0M | -$206.9M | $507.5M | $269.6M | $509.8M | $536.4M | $428.6M |
| Operating cash flow | $728.5M | $718.2M | $827.1M | $702.6M | $364.0M | $596.1M | $742.5M | $703.6M | $658.2M | $664.6M | $772.6M | $573.5M |
| Free cash flow | $728.5M | $718.2M | $827.1M | $702.6M | $364.0M | $596.1M | $742.5M | $703.6M | $658.2M | $664.6M | $772.6M | $573.5M |
| Diluted shares | 556.9M | 556.8M | 557.8M | 559.6M | 562.3M | 578.1M | 589.3M | 592.7M | 596.9M | 597.5M | 597.4M | 601.1M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $812.0M | $586.4M | $618.7M | $938.9M | $631.9M | $1.09B |
| Short-term investments | $25.0M | $21.9M | $18.8M | $16.1M | $13.2M | $12.1M |
| Total debt | $9.07B | $8.98B | $9.06B | $8.97B | $8.09B | $7.64B |
| Total assets | $19.82B | $19.82B | $19.62B | $19.35B | $18.32B | $17.61B |
| Total liabilities | $10.03B | $9.88B | $9.91B | $9.73B | $8.82B | $7.82B |
| Shareholders' equity | $9.79B | $9.94B | $9.71B | $9.62B | $9.50B | $9.79B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology